Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.

Brandl L, Zhang Y, Kirstein N, Sendelhofert A, Boos SL, Jung P, Greten F, Rad R, Menssen A.

Neoplasia. 2019 Oct;21(10):974-988. doi: 10.1016/j.neo.2019.07.009. Epub 2019 Aug 20.

2.

Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Pardo LM, Voigt AP, Alonzo TA, Wilson ER, Gerbing RB, Paine DJ, Dai F, Menssen AJ, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Brodersen LE, Loken MR.

Cytometry B Clin Cytom. 2019 Jul 11. doi: 10.1002/cyto.b.21829. [Epub ahead of print]

PMID:
31294507
3.

Component-wise testing of laser-written integrated coupled-mode beam splitters.

Guan J, Menssen AJ, Liu X, Wang J, Booth MJ.

Opt Lett. 2019 Jun 15;44(12):3174-3177. doi: 10.1364/OL.44.003174.

PMID:
31199409
4.

The c-MYC/NAMPT/SIRT1 feedback loop is activated in early classical and serrated route colorectal cancer and represents a therapeutic target.

Brandl L, Kirstein N, Neumann J, Sendelhofert A, Vieth M, Kirchner T, Menssen A.

Med Oncol. 2018 Nov 20;36(1):5. doi: 10.1007/s12032-018-1225-1.

PMID:
30460421
5.

Expression of n-MYC, NAMPT and SIRT1 in Basal Cell Carcinomas and their Cells of Origin.

Brandl L, Hartmann D, Kirchner T, Menssen A.

Acta Derm Venereol. 2019 Jan 1;99(1):63-71. doi: 10.2340/00015555-3031.

6.

Efficient Classical Algorithm for Boson Sampling with Partially Distinguishable Photons.

Renema JJ, Menssen A, Clements WR, Triginer G, Kolthammer WS, Walmsley IA.

Phys Rev Lett. 2018 Jun 1;120(22):220502. doi: 10.1103/PhysRevLett.120.220502.

PMID:
29906153
7.

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.

Voigt AP, Brodersen LE, Alonzo TA, Gerbing RB, Menssen AJ, Wilson ER, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Loken MR.

Haematologica. 2017 Dec;102(12):2058-2068. doi: 10.3324/haematol.2017.169029. Epub 2017 Sep 7.

8.

Distinguishability and Many-Particle Interference.

Menssen AJ, Jones AE, Metcalf BJ, Tichy MC, Barz S, Kolthammer WS, Walmsley IA.

Phys Rev Lett. 2017 Apr 14;118(15):153603. doi: 10.1103/PhysRevLett.118.153603. Epub 2017 Apr 10.

9.

Consistent quantitative gene product expression: #3. Invariance with age.

Loken MR, Voigt AP, Eidenschink Brodersen L, Fritschle W, Menssen AJ, Wells DA.

Cytometry A. 2016 Nov;89(11):997-1000. doi: 10.1002/cyto.a.22997. Epub 2016 Oct 18.

10.

Consistent quantitative gene product expression: #2. Antigen intensities on bone marrow cells are invariant between individuals.

Loken MR, Voigt AP, Eidenschink Brodersen L, Fritschle W, Menssen AJ, Meshinchi S, Wells DA.

Cytometry A. 2016 Nov;89(11):987-996. doi: 10.1002/cyto.a.22999. Epub 2016 Oct 18.

11.

A recurrent immunophenotype at diagnosis independently identifies high-risk pediatric acute myeloid leukemia: a report from Children's Oncology Group.

Eidenschink Brodersen L, Alonzo TA, Menssen AJ, Gerbing RB, Pardo L, Voigt AP, Kahwash SB, Hirsch B, Raimondi S, Gamis AS, Meshinchi S, Loken MR.

Leukemia. 2016 Oct;30(10):2077-2080. doi: 10.1038/leu.2016.119. Epub 2016 May 2. No abstract available.

12.

Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry workup.

Eidenschink Brodersen L, Menssen AJ, Wangen JR, Stephenson CF, de Baca ME, Zehentner BK, Wells DA, Loken MR.

Cytometry B Clin Cytom. 2015 Mar;88(2):125-35. doi: 10.1002/cyto.b.21199. Epub 2014 Dec 10.

13.

Assessment of erythroid dysplasia by "difference from normal" in routine clinical flow cytometry work-up.

Eidenschink Brodersen L, Menssen AJ, Wangen JR, Stephenson CF, de Baca ME, Zehentner BK, Wells DA, Loken MR.

Cytometry B Clin Cytom. 2014 Oct 21. doi: 10.1002/cytob.21199. [Epub ahead of print]

14.

Momentum transfer to a free floating double slit: realization of a thought experiment from the Einstein-Bohr debates.

Schmidt LP, Lower J, Jahnke T, Schößler S, Schöffler MS, Menssen A, Lévêque C, Sisourat N, Taïeb R, Schmidt-Böcking H, Dörner R.

Phys Rev Lett. 2013 Sep 6;111(10):103201. Epub 2013 Sep 5.

PMID:
25166663
15.

[c-MYC-mediated regulations in colorectal cancer].

Menssen A.

Pathologe. 2013 Nov;34 Suppl 2:274-6. doi: 10.1007/s00292-013-1819-5. German.

PMID:
24196628
16.

Observation of electron energy discretization in strong field double ionization.

Henrichs K, Waitz M, Trinter F, Kim H, Menssen A, Gassert H, Sann H, Jahnke T, Wu J, Pitzer M, Richter M, Schöffler MS, Kunitski M, Dörner R.

Phys Rev Lett. 2013 Sep 13;111(11):113003. Epub 2013 Sep 13.

PMID:
24074083
17.

Genome-wide analysis of c-MYC-regulated mRNAs and miRNAs, and c-MYC DNA binding by next-generation sequencing.

Jackstadt R, Menssen A, Hermeking H.

Methods Mol Biol. 2013;1012:145-85. doi: 10.1007/978-1-62703-429-6_11.

PMID:
24006064
18.

AP4 is a mediator of epithelial-mesenchymal transition and metastasis in colorectal cancer.

Jackstadt R, Röh S, Neumann J, Jung P, Hoffmann R, Horst D, Berens C, Bornkamm GW, Kirchner T, Menssen A, Hermeking H.

J Exp Med. 2013 Jul 1;210(7):1331-50. doi: 10.1084/jem.20120812. Epub 2013 Jun 10.

19.
20.

c-MYC and SIRT1 locked in a vicious cycle.

Menssen A, Hermeking H.

Oncotarget. 2012 Feb;3(2):112-3. No abstract available.

21.

The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop.

Menssen A, Hydbring P, Kapelle K, Vervoorts J, Diebold J, Lüscher B, Larsson LG, Hermeking H.

Proc Natl Acad Sci U S A. 2012 Jan 24;109(4):E187-96. doi: 10.1073/pnas.1105304109. Epub 2011 Dec 21.

22.

miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions.

Siemens H, Jackstadt R, Hünten S, Kaller M, Menssen A, Götz U, Hermeking H.

Cell Cycle. 2011 Dec 15;10(24):4256-71. doi: 10.4161/cc.10.24.18552. Epub 2011 Dec 15.

PMID:
22134354
23.

Differential gene expression profiling of human bone marrow-derived mesenchymal stem cells during adipogenic development.

Menssen A, Häupl T, Sittinger M, Delorme B, Charbord P, Ringe J.

BMC Genomics. 2011 Sep 24;12:461. doi: 10.1186/1471-2164-12-461.

24.

SiPaGene: A new repository for instant online retrieval, sharing and meta-analyses of GeneChip expression data.

Menssen A, Edinger G, Grün JR, Haase U, Baumgrass R, Grützkau A, Radbruch A, Burmester GR, Häupl T.

BMC Genomics. 2009 Mar 5;10:98. doi: 10.1186/1471-2164-10-98.

25.

AP4 encodes a c-MYC-inducible repressor of p21.

Jung P, Menssen A, Mayr D, Hermeking H.

Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):15046-51. doi: 10.1073/pnas.0801773105. Epub 2008 Sep 25.

26.

OTT-MAL is a deregulated activator of serum response factor-dependent gene expression.

Descot A, Rex-Haffner M, Courtois G, Bluteau D, Menssen A, Mercher T, Bernard OA, Treisman R, Posern G.

Mol Cell Biol. 2008 Oct;28(20):6171-81. doi: 10.1128/MCB.00303-08. Epub 2008 Aug 18.

27.

Induction of cullin 7 by DNA damage attenuates p53 function.

Jung P, Verdoodt B, Bailey A, Yates JR 3rd, Menssen A, Hermeking H.

Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11388-93. Epub 2007 Jun 22.

28.

Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest.

Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, Meister G, Hermeking H.

Cell Cycle. 2007 Jul 1;6(13):1586-93. Epub 2007 May 11.

PMID:
17554199
29.

Digital karyotyping reveals frequent inactivation of the dystrophin/DMD gene in malignant melanoma.

Körner H, Epanchintsev A, Berking C, Schuler-Thurner B, Speicher MR, Menssen A, Hermeking H.

Cell Cycle. 2007 Jan 15;6(2):189-98. Epub 2007 Jan 19.

PMID:
17314512
30.

Large-scale identification of c-MYC-associated proteins using a combined TAP/MudPIT approach.

Koch HB, Zhang R, Verdoodt B, Bailey A, Zhang CD, Yates JR 3rd, Menssen A, Hermeking H.

Cell Cycle. 2007 Jan 15;6(2):205-17. Epub 2007 Jan 20.

PMID:
17314511
31.

c-MYC delays prometaphase by direct transactivation of MAD2 and BubR1: identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability.

Menssen A, Epanchintsev A, Lodygin D, Rezaei N, Jung P, Verdoodt B, Diebold J, Hermeking H.

Cell Cycle. 2007 Feb 1;6(3):339-52. Epub 2007 Feb 3.

PMID:
17297307
32.

Inducible microRNA expression by an all-in-one episomal vector system.

Epanchintsev A, Jung P, Menssen A, Hermeking H.

Nucleic Acids Res. 2006;34(18):e119. Epub 2006 Sep 22.

33.

Functional epigenomics identifies genes frequently silenced in prostate cancer.

Lodygin D, Epanchintsev A, Menssen A, Diebold J, Hermeking H.

Cancer Res. 2005 May 15;65(10):4218-27.

34.
35.
36.
38.

Analysis of the TCRBV repertoire of T cells in normal, human skin: evidence for a restricted diversity.

Menssen A, Vollmer S, Trommler P, Sander C, Prinz JC.

J Invest Dermatol. 2000 Jul;115(1):66-73.

39.

Selection of conserved TCR VDJ rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris.

Prinz JC, Vollmer S, Boehncke WH, Menssen A, Laisney I, Trommler P.

Eur J Immunol. 1999 Oct;29(10):3360-8.

40.

The complete nucleotide sequence of bean yellow mosaic potyvirus RNA.

Guyatt KJ, Proll DF, Menssen A, Davidson AD.

Arch Virol. 1996;141(7):1231-46.

PMID:
8774684
41.

Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris.

Menssen A, Trommler P, Vollmer S, Schendel D, Albert E, Gürtler L, Riethmüller G, Prinz JC.

J Immunol. 1995 Oct 15;155(8):4078-83.

PMID:
7561119
43.

The En/Spm transposable element of Zea mays contains splice sites at the termini generating a novel intron from a dSpm element in the A2 gene.

Menssen A, Höhmann S, Martin W, Schnable PS, Peterson PA, Saedler H, Gierl A.

EMBO J. 1990 Oct;9(10):3051-7.

Supplemental Content

Loading ...
Support Center